MedTrace Logo

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

NCT02849977 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5966

Last updated 2022-11-15

No results posted yet for this study

Summary

The purpose of this screening study is to identify people who have a rare genetic cause of obesity - specifically three genetic variants (a change in the DNA structure) of the POMC, PCSK1 and LepR genes that are currently known to result in obesity.

This screening study will not include any investigational drugs. You will be asked to provide a DNA sample and answer some questions about your medical history and hunger.

Conditions

  • Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations

Sponsors & Collaborators

  • Rhythm Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • David Meeker · Rhythm Pharmceuticals, Inc.

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-28
Primary Completion
2020-06-09
Completion
2020-06-09

Countries

  • United States
  • Canada
  • Germany
  • Greece
  • Israel
  • Italy
  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02849977 on ClinicalTrials.gov